1,24-dihydroxyvitamin D2
LR-103 has antineoplastic activity; RN & structure in first source
Also Known As:
1,24(S)-dihydroxyvitamin D2; 1alpha,24(S)(OH)2D2; 1alpha,24(s)-dihydroxyvitamin D2; LR-103
Networked: 5
relevant articles (1 outcomes,
3 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
| 1. | Knutson, J C:
2 articles
(05/2005 - 09/2004)
|
| 2. | Strugnell, S A:
2 articles
(05/2005 - 09/2004)
|
| 3. | Wigington, D P:
2 articles
(05/2005 - 09/2004)
|
| 4. | Albertini, Mark:
1 article
(12/2015)
|
| 5. | Bailey, Howard H:
1 article
(12/2015)
|
| 6. | Douglas, Jeffrey:
1 article
(12/2015)
|
| 7. | Kolesar, Jill:
1 article
(12/2015)
|
| 8. | Ledesma, Wendy M:
1 article
(12/2015)
|
| 9. | Liu, Glenn:
1 article
(12/2015)
|
| 10. | Mulkerin, Daniel:
1 article
(12/2015)
|
Related Diseases
| 1. | Neoplasms (Cancer)
12/01/2015
- " A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer." 12/01/2015
- " The objective of this study was to determine the maximum tolerated dose and safety of LR-103, a Vitamin D analogue, in patients with advanced cancer. " 05/01/1998
- " The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines." 01/01/2005
- " 1,24(S)-dihydroxyvitamin D2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors." 05/01/1998
- " In the present study, the efficacy of the vitamin D2 analog, 1,24(S)-dihydroxyvitamin D2 (1,24(S)-(OH)2D2) in the inhibition of cancer cell proliferation and in inducing differentiation of cancer cells was compared to that of 1,25(OH)2D3. "
|
| 2. | Prostatic Neoplasms (Prostate Cancer)
|
| 3. | Breast Neoplasms (Breast Cancer)
|
|
Related Drugs and Biologics